What are the cardiovascular effects of adenosine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cardiovascular Effects of Adenosine

Adenosine is a potent vasodilator that primarily affects the microcirculation, causes transient AV nodal blockade, and has a very short half-life of less than 10 seconds, making it valuable for both diagnostic and therapeutic cardiovascular applications. 1, 2

Mechanism of Action

Adenosine exerts its cardiovascular effects through activation of specific purine receptors:

  • A1 receptors: Located in atrial/ventricular myocardium and SA/AV nodes

    • Cause negative chronotropic, dromotropic, and inotropic effects
    • Inhibit adenylyl cyclase activity
    • Activate potassium channels in cardiac tissue 2, 3
  • A2 receptors: Located in coronary endothelial and smooth muscle cells

    • Produce vasodilation
    • Stimulate adenylyl cyclase activity 2, 3

Primary Cardiovascular Effects

Electrophysiological Effects

  • AV nodal conduction: Causes transient AV block by depressing AV nodal conduction 4
  • Chronotropic effects: Negative chronotropic effect (slows heart rate) 2, 5
  • Dromotropic effects: Negative dromotropic effect (slows conduction velocity) 2
  • Inotropic effects:
    • Negative inotropic effect in atrial tissue
    • Minimal direct effect on ventricular tissue, but can counteract catecholamine-induced increases in contractility 5

Vascular Effects

  • Coronary circulation: Produces significant coronary vasodilation 1, 2
  • Systemic circulation: Causes peripheral vasodilation leading to mild-to-moderate reduction in systolic, diastolic, and mean arterial pressure 2
  • Pulmonary circulation: Causes pulmonary vasodilation 6

Clinical Applications

Supraventricular Tachycardia Management

  • Highly effective in terminating AV nodal re-entrant tachycardias (78-96% success rate) 1
  • Recommended dosing:
    • Initial: 3 mg rapid IV bolus with saline flush
    • If ineffective after 1-2 minutes: 6 mg
    • Maximum dose: 12 mg 4
  • Should be administered via proximal IV as a rapid bolus 1

Diagnostic Applications

  • Coronary artery disease assessment: Used to induce coronary vasodilation during cardiac stress testing 1, 7
  • Tachycardia differentiation: Helps distinguish supraventricular from ventricular tachycardias 1, 7
  • Can unmask atrial flutter or atrial tachycardia 1

Pharmacokinetics

  • Distribution: Rapid cellular uptake via specific transmembrane nucleoside transport system 2
  • Metabolism: Intracellular adenosine is metabolized via:
    • Phosphorylation to adenosine monophosphate by adenosine kinase
    • Deamination to inosine by adenosine deaminase 2
  • Elimination: Extremely short half-life (<10 seconds) in whole blood 2, 7

Side Effects and Precautions

Common Side Effects

  • Flushing
  • Chest discomfort/pain
  • Dyspnea
  • Transient complete heart block 4, 7

Serious Adverse Effects (Rare)

  • Significant hypotension
  • Tachycardia
  • Bronchospasm (in patients with asthma) 1, 4

Contraindications and Cautions

  • Asthma: Contraindicated in severe asthma due to risk of bronchospasm 1, 4
  • Drug interactions:
    • Enhanced effect with dipyridamole
    • Reduced effect with theophylline/xanthine derivatives
    • Higher rates of heart block when used with carbamazepine 1, 4

Clinical Pearls and Pitfalls

  • Administration technique: Must be given as a rapid IV bolus followed by saline flush to ensure delivery to the central circulation 1
  • Monitoring: Always administer in a monitored setting due to potential for transient complete heart block 4
  • Diagnostic value: Continuous ECG recording during administration helps distinguish drug failure from successful termination with immediate arrhythmia reinitiation 1
  • Valsalva avoidance: Patients should avoid Valsalva maneuvers during IV adenosine infusion as this can interrupt drug delivery and cause fluctuations in coronary blood flow 1
  • Pre-excited tachycardias: Use with caution as adenosine may produce ventricular fibrillation in patients with coronary artery disease or accelerate ventricular response in pre-excited atrial fibrillation 1

Adenosine's unique cardiovascular profile and extremely short half-life make it particularly valuable in both diagnostic and therapeutic settings where rapid, transient effects are desired.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Adenosine, the heart, and coronary circulation.

Hypertension (Dallas, Tex. : 1979), 1991

Guideline

Adenosine Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Adenosine and the Cardiovascular System: The Good and the Bad.

Journal of clinical medicine, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.